Article
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.
EMBO molecular medicine - 11 Jan 2022
Lu Yue, Fan Zhenzhen, Zhu Su-Jie, Huang Xiaoxing, Zhuang Zhongji, Li Yunzhan, Deng Zhou, Gao Lei, Hong Xuehui, Zhang Ting, Li Li, Sun Xihuan, Huang Wei, Zhang Jingfang, Liu Yan, Zhang Baoding, Jiang Jie, Gui Fu, Wang Zheng, Li Qiyuan, Song Siyang, Huang Xin, Wu Qiao, Chen Lanfen, Zhou Dawang, Zhang Jianming, Yun Cai-Hong, Chen Liang, Deng Xianming
Abstract excerpt
More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due to acquired secondary mutations in the ALK kinase domain, such as the gatekeeper mutation L1196M and the most refractory...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.